Modified AAV Capsid Proteins for Enhanced Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adeno-associated virus (AAV) vectors face inefficiencies in delivering heterologous nucleic acid molecules to target cells and elicit an immune response, limiting their use in gene therapy and immunization applications.
Innovation Solution
Modification of AAV capsid proteins by introducing non-native amino acids at specific positions involved in receptor binding, enhancing transduction efficiency and reducing immunogenicity through altered receptor recognition and antibody neutralization resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current AAV vectors are used for gene delivery, then transduction efficiency is limited, but modifying capsid proteins increases complexity
Solution Approach 1:
The patent applies parameter changes by systematically modifying specific amino acid residues at defined positions in the AAV capsid protein structure. This includes substituting residues at positions involved in receptor binding (such as positions 58-60, 84-86, 100-102 in the VP1 protein) to alter receptor specificity and enhance transduction efficiency while maintaining capsid integrity
Solution Approach 2:
The invention implements local quality by making targeted modifications at specific locations on the capsid surface rather than global changes. The modifications are concentrated at receptor binding sites and antibody interaction regions, allowing enhanced transduction and reduced immunogenicity without compromising overall capsid structure and function
2Reliability
If AAV vectors are used repeatedly for gene therapy, then immunogenicity limits reuse, but modifying capsid proteins to reduce immunogenicity may affect transduction efficiency
Solution Approach 1:
The patent modifies capsid protein parameters by changing amino acid sequences at positions involved in antibody binding (such as epitopic regions). These parameter changes reduce recognition by pre-existing neutralizing antibodies, enabling repeated administrations while maintaining transduction capability through preservation of receptor binding functions
Solution Approach 2:
The invention uses alternative receptor binding mechanisms as intermediaries. By modifying capsid proteins to use different or additional cell surface receptors, the vectors can evade neutralizing antibodies that target original receptor interactions, thereby enabling repeated use without sacrificing transduction efficiency
Data Source
AI summary
A modified adeno-associated virus (AAV) capsid protein comprising at least one non-native amino acid that confers to the modified AAV particles new properties, such as increased transduction efficiency and reduced immunogenicity. These modified AAV proteins and particles are particularly useful for gene therapy and the treatment of various diseases and conditions.